Navigation Links
Tosedostat OPAL Study Final Results Selected for Oral Presentation at the 2011 American Society of Hematology (ASH) Annual Meeting
Date:12/6/2011

rather than intercalation with DNA -- pixantrone alkylates DNA -- forming stable DNA adducts with particular specificity for CpG-rich, hyper-methylated sites. These structural differences resulted in significantly enhanced anti-lymphoma activity compared to doxorubicin in preclinical models. In addition, the structural motifs on anthracycline-like agents that are responsible for the generation of oxygen free radicals and the formation of toxic drug-metal complexes have also been modified in pixantrone in an effort to prevent the binding of iron and perpetuation of superoxide production -- both of which are the putative mechanism for anthracycline induced acute cardiotoxicity. These novel pharmacologic differences may allow re-introduction of anthracycline-like potency in the treatment of relapsed/refractory diffuse large lymphoma without unacceptable rates of cardiotoxicity.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone and tosedostat include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone and tosedostat in particular including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of NHL and/or other tumors as determined by the U.S. Food and Drug Administration (the "FDA") and/or the European Medicines Agency (th
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmathene Announces Publication of Phase I Study Results for Anthrax Anti-toxin Valortim®
2. Aethlon Medical Announces Approval and Initiation of Cancer Research Study to Target Tumor-Secreted Exosomes
3. New Study Shows AFECTAIR® Significantly Improved Delivery of Nitric Oxide Under Simulated Neonatal Ventilatory Conditions
4. First Patient Enrolled in Therakos Phase Two Study for Treatment of Graft-versus-Host Disease
5. New Gene Study of ADHD Points to Defects in Brain Signaling Pathways
6. RECITAL Study Presents Excellent Outcomes and Rapid Patient Recovery With Revolutionary Femoral Access Procedure
7. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome
8. Ceregene Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinsons Disease
9. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
10. BioMarin Initiates Phase 2 Study for GALNS in Patients Under Five Years of Age With MPS IVA
11. New Study Points to Novel Mechanism by Which Tumors Escape Recognition by the Immune System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... NEW YORK , Sept. 2, 2015 /PRNewswire/ ... equipment market studies the current and future prospects ... monitoring of patient,s health and assists medical practitioners ... track the disease progression during treatment. Multi-parameter patient ... care and chronic disease. Geriatric population is observed ...
(Date:9/2/2015)... NEW YORK , Sept. 2, 2015 /PRNewswire/ ... dystrophy is an X-linked disease, which generally affects ... muscle degeneration and weakness. The disease is caused ... result in the lack of production of dystrophin ... in individuals. The lack of dystrophin weakens muscle ...
(Date:9/2/2015)... Sept. 2, 2015 Transaction ... base with highly profitable specialty products , ... growth potential with 11 product applications pending at ... certifications  , Provides medium and longer term ... including eight controlled substances , Adds development ...
Breaking Medicine Technology:Multi-parameter Patient Monitoring Equipment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 2Multi-parameter Patient Monitoring Equipment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 3Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 2Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 3Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 4Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 5Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 6
... Cardiac Science Corporation (Nasdaq: CSCX ... AED ) and diagnostic cardiac monitoring devices, today announced ... 30, 2009, in line with its previous guidance. The Company ... field product update and a non-cash charge of $44.0 million ...
... Nov. 9 Momentum is building for the early December ... India pharma ingredients, services and technologies event. A combined total of ... countries are expected at the Bombay Exhibition Centre for the ... In addition to high quality exhibitors, the 2009 events include two ...
Cached Medicine Technology:Cardiac Science Announces Third Quarter Results 2Cardiac Science Announces Third Quarter Results 3Cardiac Science Announces Third Quarter Results 4Cardiac Science Announces Third Quarter Results 5Cardiac Science Announces Third Quarter Results 6Cardiac Science Announces Third Quarter Results 7Cardiac Science Announces Third Quarter Results 8Cardiac Science Announces Third Quarter Results 9Cardiac Science Announces Third Quarter Results 10Cardiac Science Announces Third Quarter Results 11Cardiac Science Announces Third Quarter Results 12Cardiac Science Announces Third Quarter Results 13Cardiac Science Announces Third Quarter Results 14Cardiac Science Announces Third Quarter Results 15Cardiac Science Announces Third Quarter Results 16Cardiac Science Announces Third Quarter Results 17Cardiac Science Announces Third Quarter Results 18Cardiac Science Announces Third Quarter Results 19Cardiac Science Announces Third Quarter Results 20Forecast Looks Good for India Pharma Shows 2Forecast Looks Good for India Pharma Shows 3
(Date:9/2/2015)... ... September 02, 2015 , ... Based in Beverly Hills, Luxury Line Auto ... luxury vehicles based on which of the latest and greatest vehicles their customers want ... in pursuit of this goal: a 2015 Rolls Royce Wraith rental in Los ...
(Date:9/2/2015)... ... September 02, 2015 , ... In “Failure Lab: Weight Loss Surgery ... on August 25th, writer Akela Stanfield detailed her lifelong struggle with obesity that eventually ... she had always seen herself as someone who would lose weight through sheer self-control, ...
(Date:9/2/2015)... ... 2015 , ... Care Providers and their medical billing service ... EOBs, payments, and payment related documents. AD-EOB A/R helps them sort, index and ... with one efficient process and interface,“ stated Rich Caproni, AliusDoc’s Director of Business ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... academic partnership has earned international recognition as a premier center for treatment of ... cause sudden, catastrophic internal bleeding and stroke. , Cure HHT, previously known ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... companies, has completed a recapitalization with new investment partners Beecken Petty O’Keefe ... Group each offer extensive expertise and connections within the healthcare industry, which ...
Breaking Medicine News(10 mins):Health News:Luxury Line Auto Rental Announces Addition of the Rolls Royce Wraith to their Luxury Fleet 2Health News:Recent Editorial on Bariatric Surgery Acceptance Illuminates a Typical Journey Towards Weight Loss Surgery, Notes Dr. Michael Feiz 2Health News:AliusDoc Launches Enhanced AD-EOB A/R Data Capture Solution to Streamline Processing of Payment-Related Documents Together with EOBs 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 4Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 2Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 3Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 4
... Response Essentially Met but Donations Still Needed to Prepare,for ... WASHINGTON, May 5 The American Red Cross,today ... the Southeastern,Virginia tornadoes but donations to its Disaster Relief ... the next disaster, particularly with the,beginning of hurricane season ...
... Integrated Approach, WASHINGTON, May 5 ... Kenya, and Tanzania -- face the interconnected,challenges ... environmental,degradation. But some innovative development programs are ... linked problems., On May 8th, three ...
... SYDNEY, Australia, May 5 ,HeartWare Limited (ASX: HTW) ... the United States Food and Drug Administration,(FDA) of ... product,the HeartWare(R) Left Ventricular Assist System (LVAS)., ... FDA enables the Company,to immediately commence its U.S. ...
... growth factor receptor found abundantly on the surface of ... also protects tumor cells from starvation by a newly ... D. Anderson Cancer Center report in the May 5 ... receptor (EGFR) stabilizes another cell membrane protein that channels ...
... cancerous, study shows , , MONDAY, May 5 (HealthDay News) ... starts harmless colon polyps on their journey to becoming ... Helsinki research, published online in Cancer Cell , ... of normal organs in embryos, is produced in excess ...
... 4, 2008 MedImmune today announced that researchers ... 3 study involving motavizumab, an investigational monoclonal antibody ... to prevent serious disease caused by respiratory syncytial ... OBrien, M.D., M.P.H., associate professor at the Center ...
Cached Medicine News:Health News:Generous Donors Allow Red Cross to Respond Swiftly and Effectively to Southeastern Virginia Tornadoes 2Health News:Generous Donors Allow Red Cross to Respond Swiftly and Effectively to Southeastern Virginia Tornadoes 3Health News:East African Experts Discuss Population, Health, Environment at Wilson Center 2Health News:HeartWare Receives Conditional Approval of IDE 2Health News:HeartWare Receives Conditional Approval of IDE 3Health News:Unexpected role: EGFR protects cancer cells from starving 2Health News:Unexpected role: EGFR protects cancer cells from starving 3Health News:Phase 3 data Re: Anti-RSV antibody to be presented at Pediatric Academic Societies Annual Meeting 2
... a leading provider of immunofluorescence assays, with ... that includes kits for autoimmune diseases, infectious ... conjugates and components. Our Impact IFA Test ... substrates and kit sizes to choose from. ...
... Inverness Medical Professional Diagnostics is a leading ... IFA and DFA test menu that includes ... STDs as well as miscellaneous conjugates and ... you a wide assortment of substrates and ...
... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
Medicine Products: